CVS.US Weekly Report · 2026-W35
Weekly Overview
CVS Health remained essentially flat this week, closing at 93.06 USD, up just 0.04% from the prior week’s close. Compelling low valuations stand in stark contrast to overwhelmingly bullish institutional ratings, yet trading volume contracted notably and retail capital experienced slight outflows. Market momentum appears muted, as if awaiting a clearer catalyst.
Price Action
The stock closed at 93.06 USD compared to 93.02 USD at the end of the previous trading week, representing a gain of 0.04%. Intraweek range: 93.01–93.93 USD, with amplitude under 1%, reflecting subdued price action throughout the week.
Daily average volume this week was approximately 5.76 million shares, considerably below the 60-day median of roughly 7–8 million, indicating a contraction phase. Daily volumes ranged from 4.10 to 9.23 million shares; the peak occurred on August 24 with over 9.2 million shares traded, followed by progressive decline for the remainder of the week.
Valuation & Earnings
Current P/E of 24.34x and P/B of 1.49x. Historically, the price-to-book ratio at 1.49 sits in the lower end of the 5-year range, trading cheaper than 35.46% of all days in that period. The company ranks 11th among 74 peers in the industry.
Latest quarterly results (Q2 2026) reported EPS of 2.31 USD, up 189% year-over-year and stable sequentially. Operating revenue reached 105.455 billion USD, up 7.14% year-over-year; net profit of 2.979 billion USD surged 192% year-over-year. Operating profit of 4.072 billion USD rose 47.59% year-over-year, indicating robust earnings momentum.
Consensus EPS projection for the full year stands at 8.156 USD.
Capital Flow & Institutional View
As of August 28, capital flows show divergence. Large institutions and mid-cap investors both posted net inflows; retail investors experienced minor net outflows. This composition suggests professional conviction against retail caution.
Institutional ratings exhibit exceptional concentration: 18 strong buys, 6 buys, 3 holds, and zero sell ratings. Ratings were last updated August 26 with a consensus price target of 116.08 USD, implying 24.74% upside from current levels. Notably, institutional ratings are relatively lagging signals and should not be mistaken for real-time market consensus.
Weekly News
This week’s coverage focused on competitive dynamics within healthcare services and the company’s operating fundamentals. Piper Sandler reiterated its buy rating on August 26; Wells Fargo and Bernstein both recently maintained buy positions. Community health initiatives gained industry recognition. Additionally, structural reorganization within large healthcare conglomerates continued, with Mark Cuban backing proposals to break up major industry players.
- CVS Health Corp. Stock Outperforms Competitors Despite Losses On The Day
- Mark Cuban Backs Plan to Break Up Big Medicine
- CVS Health Corp. Stock Outperforms Competitors On Strong Trading Day
- Piper Sandler Remains a Buy on CVS Health (CVS)
- CVS Health Stock Is Beating the Market in 2026. Here’s Why Wall Street Thinks It Can Soar Another 22%.
- Wells Fargo Keeps Their Buy Rating on CVS Health (CVS)
- Bernstein Keeps Their Buy Rating on CVS Health (CVS)
- CVS Caremark survey shows 91% of employers worry about rising prescription drug prices
- CVS Health Corp. Stock Underperforms Monday When Compared To Competitors
- CVS Health: Every Community Deserves a Healthier Heart
Signal Consistency & Contradictions
Multiple dimensions reveal an interesting divergence. Low valuation, robust earnings, overwhelmingly bullish institutional ratings, and sustained large-cap fund inflows all point upward. Yet trading volume compressed substantially this week and retail capital edged lower, with price action remaining flat.
One interpretation: institutional buy ratings may simply reflect rational pricing following Q2 earnings delivery rather than a new bullish catalyst. Compressed volume and cautious retail positioning suggest the market awaits clearer directional conviction. The coexistence of cheap valuation, bullish ratings, and thin trading signals lingering disagreement about the path ahead.